Anti-BCL9L Antibody Picoband® Fluoro647 Conjugated

B-cell CLL/lymphoma 9 like is a protein that in humans is encoded by the BCL9L gene. It is mapped to 11q23.3. Bcl-9 (B-cell lymphoma 9; also Protein legless homolog) is a transcriptional regulator that belongs to the Bcl-9 family of proteins. It is expressed in multiple tissues and serves to recruit Pygopus to the Wnt-pathway beta -catenin-TCF complex in the nucleus. Bcl-9 and Bcl-9-2 are considered evolutionary duplicates of Legless that perform the same task with different regulation. Human Bcl-9 is 1426 amino acids (aa) in length. It contains one phosphothreonine and three phosphoserine sites that have been identified so far, two poly-Pro regions (aa 514-517 and 970-973), and one poly-Ala segment (aa 900-903) . There is one potential alternate start site at Met27, and a variant isoform exists that shows a four aa substitution for aa 13911426. Over aa 1009-1328, human Bcl-9 is 96% aa identical to mouse Bcl-9.

Expressed in breast, ductal and invasive ductal carcinomas of the breast, sporadic colorectal adenomas and carcinomas (at protein level) . Expressed in fetal brain. Expressed in lung, amygdala, eye, prostate, pancreatic and prostate cancers, head and neck tumors and embryonal tumor.

Transcriptional regulator that acts as an activator. Promotes beta-catenin transcriptional activity. Plays a role in tumorigenesis. Enhances the neoplastic transforming activity of CTNNB1.

1. Brembeck, F. H., Schwarz-Romond, T., Bakkers, J., Wilhelm, S., Hammerschmidt, M., Birchmeier, W. Essential role of BCL9-2 in the switch between beta-catenin's adhesive and transcriptional functions. Genes Dev. 18: 2225-2230, 2004. 2. Katoh, M., Katoh, M. Identification and characterization of human BCL9L gene and mouse Bcl9l gene in silico. Int. J. Molec. Med. 12: 643-649, 2003.